NCT07091630 (emnergize) is a Phase 3 clinical trial of Empasiprubart IV in Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by argenx.

Who is sponsoring NCT07091630?

NCT07091630 is sponsored by argenx.

What drugs are being tested in NCT07091630?

Interventions in NCT07091630: Empasiprubart IV, Placebo IV.

What condition does NCT07091630 study?

NCT07091630 studies Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Is NCT07091630 still recruiting?

NCT07091630 is currently recruiting now. Last updated 11 March 2026.

Last reviewed 2026-03-11 · How we verify

NCT07091630: emnergize

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

Recruiting now Phase 3 Last updated 11 March 2026

What this trial tests

Phase 3 trial testing Empasiprubart IV in Chronic Inflammatory Demyelinating Polyneuropathy in 160 participants. Currently enrolling.

Timeline

16 September 2025

Primary endpoint
7 October 2027

23 January 2031

Quick facts

Lead sponsor	argenx
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	160
Start date	16 September 2025
Primary completion	7 October 2027
Estimated completion	23 January 2031
Sites	19 locations across Georgia, Japan, South Korea, China, United States

Drugs / interventions tested

Empasiprubart IV — full drug profile →
Placebo IV — full drug profile →

Conditions studied

Chronic Inflammatory Demyelinating Polyneuropathy — all drugs for Chronic Inflammatory Demyelinating Polyneuropathy →
CIDP — all drugs for CIDP →
Chronic Inflammatory Demyelinating Polyradiculoneuropathy — all drugs for Chronic Inflammatory Demyelinating Polyradiculoneuropathy →

Sponsor

argenx — full company profile →

Who can join

18 and older, any sex, with Chronic Inflammatory Demyelinating Polyneuropathy or CIDP. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emnergize

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Real-world treatment utilization in adults with chronic inflammatory demyelinating polyneuropathy in the United States.
Blein C, Karam C, Arvin-Berod C, Gelinas D, et al · · 2025 · PMID 41696747 · DOI 10.3389/fneur.2025.1726857

Verify or expand the search:

Other trials of Empasiprubart IV

Trials testing the same drug.

NCT07294170 — ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Particip · recruiting
NCT07284420 — ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With · Phase 2 · recruiting

Other recruiting trials for Chronic Inflammatory Demyelinating Polyneuropathy

Currently open trials in the same condition.

NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
NCT07154524 — Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · recruiting
NCT07027111 — Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP · Phase 2 · active not recruiting
NCT06858579 — A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy · Phase 3 · recruiting
NCT06290141 — A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) · Phase 3 · recruiting

Other argenx trials

Trials by the same sponsor.

NCT07377396 — A Study to Assess the Safety of ARGX-124 in Healthy Volunteers · Phase 1 · recruiting
NCT07287982 — A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration · Phase 2 · recruiting
NCT07294170 — ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Particip · recruiting
NCT07284420 — ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With · Phase 2 · recruiting
NCT06968338 — A Study to Assess the Safety of ARGX-213 in Healthy Volunteers · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07091630 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by argenx
Last refreshed: 11 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07091630.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing